Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Tuesday, February 2, 2010

Pervasis cleared to begin Phase 3 drug trial

By Julie M. Donnelly

Pervasis Therapeutics Inc. said Tuesday that the U.S. Food and Drug Administration has cleared the way for the Cambridge-based company to begin its Phase 3 trial of its drug candidate to treat symptoms linked to end-stage renal disease.

The drug target, called Vascugel, will be tested in approximately 390 patients with end-stage renal disease. Pervasis plans to start the drug trial this year, and, if the results are positive, to submit the drug for market approval.

Pervasis recently published positive trial results for Vascugel in the December issue of the Journal of Vascular Surgery.

Pervasis develops technologies to identify drug targets for vascular diseases, inflammatory diseases and orthopedic diseases.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. The company raised $10 million in September as part of a third round of funding.

 

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women’s wisdom comes back around

By Michelle Lang If you’ve ever heard the lyrics to Brad Paisley’s “Letter to Me”, you know that the country crooner made a song of taking his adult wisdom and imparting it on his 17-year-old self, reminding him not to bother arguing with his dad, to enjoy the adventure of his date with Bridget, and to thank his teacher for spending time with him. The same concept is done daily by pa...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio